Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 273

1.

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.

Kristensen H, Thomsen AR, Haldrup C, Dyrskjøt L, Høyer S, Borre M, Mouritzen P, Ørntoft TF, Sørensen KD.

Oncotarget. 2016 Apr 23. doi: 10.18632/oncotarget.8953. [Epub ahead of print]

PMID:
27120795
2.

Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.

Haldrup C, Lynnerup AS, Storebjerg TM, Vang S, Wild P, Visakorpi T, Arsov C, Schulz WA, Lindberg J, Grönberg H, Egevad L, Borre M, Ørntoft TF, Høyer S, Sørensen KD.

Mol Oncol. 2016 Feb 9. pii: S1574-7891(16)00022-3. doi: 10.1016/j.molonc.2016.02.001. [Epub ahead of print]

PMID:
26905753
3.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, Borre M, Agerbæk M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00058-0. doi: 10.1016/j.eururo.2016.01.007. [Epub ahead of print]

PMID:
26803478
4.

Prevalence of the HOXB13 G84E mutation in Danish men treated by radical prostatectomy and correlations with prostate cancer risk and aggressiveness.

Storebjerg TM, Høyer S, Kirkegaard P, Bro F; Lu Camp, Orntoft TF, Borre M, Sørensen KD.

BJU Int. 2016 Jan 18. doi: 10.1111/bju.13416. [Epub ahead of print]

PMID:
26779768
5.

Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.

Mortensen MM, Høyer S, Lynnerup AS, Ørntoft TF, Sørensen KD, Borre M, Dyrskjøt L.

Sci Rep. 2015 Nov 2;5:16018. doi: 10.1038/srep16018.

6.

Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.

Ørntoft MB, Nielsen HJ, Ørntoft TF, Andersen CL; Danish Study Group on Early Detection of Colorectal Cancer.

BMC Cancer. 2015 Oct 29;15:819. doi: 10.1186/s12885-015-1832-6.

7.

Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis.

Mørk N, Kofod-Olsen E, Sørensen KB, Bach E, Ørntoft TF, Østergaard L, Paludan SR, Christiansen M, Mogensen TH.

Genes Immun. 2015 Dec;16(8):552-66. doi: 10.1038/gene.2015.46. Epub 2015 Oct 29.

PMID:
26513235
8.

High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.

Strand SH, Hoyer S, Lynnerup AS, Haldrup C, Storebjerg TM, Borre M, Orntoft TF, Sorensen KD.

Clin Epigenetics. 2015 Oct 15;7:111. doi: 10.1186/s13148-015-0146-5. eCollection 2015.

9.

BS-SNPer: SNP calling in bisulfite-seq data.

Gao S, Zou D, Mao L, Liu H, Song P, Chen Y, Zhao S, Gao C, Li X, Gao Z, Fang X, Yang H, Ørntoft TF, Sørensen KD, Bolund L.

Bioinformatics. 2015 Dec 15;31(24):4006-8. doi: 10.1093/bioinformatics/btv507. Epub 2015 Aug 28.

10.

Functional IRF3 deficiency in a patient with herpes simplex encephalitis.

Andersen LL, Mørk N, Reinert LS, Kofod-Olsen E, Narita R, Jørgensen SE, Skipper KA, Höning K, Gad HH, Østergaard L, Ørntoft TF, Hornung V, Paludan SR, Mikkelsen JG, Fujita T, Christiansen M, Hartmann R, Mogensen TH.

J Exp Med. 2015 Aug 24;212(9):1371-9. doi: 10.1084/jem.20142274. Epub 2015 Jul 27.

11.

SMAP: a streamlined methylation analysis pipeline for bisulfite sequencing.

Gao S, Zou D, Mao L, Zhou Q, Jia W, Huang Y, Zhao S, Chen G, Wu S, Li D, Xia F, Chen H, Chen M, Ørntoft TF, Bolund L, Sørensen KD.

Gigascience. 2015 Jul 1;4:29. doi: 10.1186/s13742-015-0070-9. eCollection 2015.

12.

Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium.

Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. Epub 2015 Apr 2.

13.

Profiling of circulating microRNAs for prostate cancer biomarker discovery.

Haldrup C, Kosaka N, Ochiya T, Borre M, Høyer S, Orntoft TF, Sorensen KD.

Drug Deliv Transl Res. 2014 Feb;4(1):19-30. doi: 10.1007/s13346-013-0169-4.

PMID:
25786615
14.

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Ørntoft TF, Andersen CL.

Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.

PMID:
25654990
15.

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

Mortensen MM, Høyer S, Orntoft TF, Sørensen KD, Dyrskjøt L, Borre M.

BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.

16.

Comparative analysis of discrete exosome fractions obtained by differential centrifugation.

Jeppesen DK, Hvam ML, Primdahl-Bengtson B, Boysen AT, Whitehead B, Dyrskjøt L, Orntoft TF, Howard KA, Ostenfeld MS.

J Extracell Vesicles. 2014 Nov 6;3:25011. doi: 10.3402/jev.v3.25011. eCollection 2014.

17.

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF.

Cancer Res. 2014 Oct 15;74(20):5758-71. doi: 10.1158/0008-5472.CAN-13-3512. Epub 2014 Sep 26.

18.

Prognostic DNA methylation markers for prostate cancer.

Strand SH, Orntoft TF, Sorensen KD.

Int J Mol Sci. 2014 Sep 18;15(9):16544-76. doi: 10.3390/ijms150916544. Review.

19.

Molekylær medicin og den dybe sekventering.

Orntoft TF, Nielsen FC.

Ugeskr Laeger. 2014 Jun 2;176(11A). pii: V66258. Danish. No abstract available.

PMID:
25186712
20.

High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.

Laurberg JR, Jensen JB, Schepeler T, Borre M, Ørntoft TF, Dyrskjøt L.

BMC Cancer. 2014 Aug 30;14:638. doi: 10.1186/1471-2407-14-638.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk